Unknown

Dataset Information

Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis.


ABSTRACT:

Objectives

Cerivastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor withdrawn from the market because of serious adverse effects, is metabolized primarily by CYP2C8. The occurrence of associated myotoxicity and rhabdomyolysis were attributed to altered cerivastatin pharmacokinetics on account of gemfibrozil-inhibition or genetic variations in CYP2C8 and drug transporters involved in cerivastatin clearance. However, the effect of CYP2C8 genetic variation on cerivastatin metabolism has not been fully elucidated.

Methods

In this study, patients (n=126) with confirmed cases of rhabdomyolysis after cerivastatin administration had their CYP2C8 gene resequenced and the metabolism of cerivastatin by the discovered CYP2C8 variants was assessed in proteins expressed i

SUBMITTER: Kaspera R 

PROVIDER: S-EPMC2993694 | biostudies-literature | 2010 Oct

REPOSITORIES: biostudies-literature